КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ КОМОРБИДНОГО ТЕЧЕНИЯ ЖЕЛЧНОКАМЕННОЙ БОЛЕЗНИ И НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
Abstract
Желчнокаменная болезнь (ЖКБ) и неалкогольная жировая болезнь печени (НАЖБП) относятся к наиболее распространённым заболеваниям гепатобилиарной системы. Общность патогенетических механизмов, включая ожирение, инсулинорезистентность, дислипидемию и метаболический синдром, способствует их частому коморбидному течению. Сочетание данных патологий приводит к более выраженным метаболическим нарушениям и ухудшению клинического течения заболевания.
References
1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl.):S47-64. doi:10.1016/j.jhep.2014.12.012
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol. 2017;11:915- 9. doi: 10.1016/j.jacl.2017.04.115
4. Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4. (In Russ.) doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728- 36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol. 2017;5:384-93. doi:10.14218/JCTH.2017.00013
7. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Exp Clin Gastroenterol. 2018;155(7):43-51. (In Russ.) eLIBRARY ID: 38200880
8. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Med Sovet. 2015;13:58-63. (In Russ.) doi: 10.21518/2079-701X2015-13-58-63
9. Zhou D, Fan J-G. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. J Siberian Med Sci. 2019;3:63-73. (In Russ.)
11. Livzan MA, Gaus OV, Nikolaev NA, Krolevets TS. NAFLD: comorbidity and associated diseases. Exp Clin Gastroenterol. 2019;170(10):57-65. (In Russ.) doi: 10.31146/1682-8658-ecg-170-10-57-65
12. Jaruvongvanich V, Sanguankeo A, Upala S. Significant association between gallstone disease and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Dis Sci. 2016;61:2389- 96. doi: 10.1007/s10620-016-4125-2
